Singapore, May 7 -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has been selected for the Korea Disease Control and Prevention Agency (KDCA)'s Priority Infectious Disease Pandemic Preparedness Rapid R&D Support Programme.

This government-led initiative aims to develop vaccines against avian influenza - identified as a high-risk candidate for the next pandemic. SK bioscience was chosen for its proven technological capabilities as the only domestic company to have commercialized cell-culture-based vaccines for both influenza and COVID-19.

Under the program, SK bioscience and KDCA will co-invest approximately KRW 5.25 billion ($3.7 million) in early-stage devel...